ARTICLE | Clinical News
RSLV-132: Phase II started
August 11, 2014 7:00 AM UTC
Resolve began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate weekly 0.3-10 mg/kg IV RSLV-132 for 4 weeks in about 32 SLE patients. In February 2013, Resolve grant...